Tweet
ELI LILLY WARNS THAT ARMENIAN HEALTH MINISTRY ABOUT TO BUY POOR QUALITY AND EXPENSIVE INSULIN FOR CHILDREN
YEREVAN, July 15. / ARKA /
Silva Barsegyan, the regional manager of Eli Lilly pharmaceutical
company, warned today that the Armenian health ministry is about to
buy a large batch of poor quality and expensive insulin for children.
Speaking to journalists, she said on June 18 Eli Lilly had received
a written notification from the health ministry saying it wanted to
buy insulin for children directly from the manufacturer and asked
the company to submit proposals.
She said although she had only one day, she got in touch with the
financial CEO of the company and negotiated a reasonable price.
However, soon she learned that the ministry was negotiating with a
French Sanofi-Aventis, which proposed a price significantly higher
than that of Eli Lilly.
To specify she said Eli Lilly offers a 10-milliliter vial of high
quality insulin for 2,103.7 drams, while Sanofi-Aventis asks 3,267
drams for a 10-milliliter vial of semi-synthetic insulin.
"The government intends to purchase 126,000 10-milliliter vials of
insulin mixture of short-term and medium-term effect, 420,000 vials
of short-term effect insulin and 858,000 vials of medium-term effect
insulin. As a result, if these drugs are bought from the French
company, the government will overpay about 251.7 million drams and
bring in much lower quality insulin. It is a violation of the interests
of the state ", she said.
She said if the insulin were bought from Eli Lilly the saved amount
would be enough to provide 300 insulin-dependent children with analogue
pen-syringes, not with vials.
Barsegyan stressed that when procuring drugs the government needs to
take into account three basic qualities that characterize the drug:
safety, efficiency and availability.
"But in Armenia when making procurements these rules are not observed
due to non-professional approach," she said.
She said this is the situation regarding purchase of anti-diabetic
pills from Indian Perdaman for which the ministry of health is going
to spend about 390 million drams in the second half of the year, while
a correct calculation of costs shows that as much as 50 million drams
would be enough. She stressed that the drugs of the Indian company
were not even registered in India itself.
ARKA asked the ministry of health for comments,
but it said explanations will be provided
later. ($ 1 - 409.93 drams). -0- - See more at:
http://arka.am/en/news/society/eli_lilly_warns_that_armenian_health_ministry_abou t_to_buy_poor_quality_and_expensive_insulin_for_ch/#sthash.y5UTS9LP.dpuf
YEREVAN, July 15. / ARKA /
Silva Barsegyan, the regional manager of Eli Lilly pharmaceutical
company, warned today that the Armenian health ministry is about to
buy a large batch of poor quality and expensive insulin for children.
Speaking to journalists, she said on June 18 Eli Lilly had received
a written notification from the health ministry saying it wanted to
buy insulin for children directly from the manufacturer and asked
the company to submit proposals.
She said although she had only one day, she got in touch with the
financial CEO of the company and negotiated a reasonable price.
However, soon she learned that the ministry was negotiating with a
French Sanofi-Aventis, which proposed a price significantly higher
than that of Eli Lilly.
To specify she said Eli Lilly offers a 10-milliliter vial of high
quality insulin for 2,103.7 drams, while Sanofi-Aventis asks 3,267
drams for a 10-milliliter vial of semi-synthetic insulin.
"The government intends to purchase 126,000 10-milliliter vials of
insulin mixture of short-term and medium-term effect, 420,000 vials
of short-term effect insulin and 858,000 vials of medium-term effect
insulin. As a result, if these drugs are bought from the French
company, the government will overpay about 251.7 million drams and
bring in much lower quality insulin. It is a violation of the interests
of the state ", she said.
She said if the insulin were bought from Eli Lilly the saved amount
would be enough to provide 300 insulin-dependent children with analogue
pen-syringes, not with vials.
Barsegyan stressed that when procuring drugs the government needs to
take into account three basic qualities that characterize the drug:
safety, efficiency and availability.
"But in Armenia when making procurements these rules are not observed
due to non-professional approach," she said.
She said this is the situation regarding purchase of anti-diabetic
pills from Indian Perdaman for which the ministry of health is going
to spend about 390 million drams in the second half of the year, while
a correct calculation of costs shows that as much as 50 million drams
would be enough. She stressed that the drugs of the Indian company
were not even registered in India itself.
ARKA asked the ministry of health for comments,
but it said explanations will be provided
later. ($ 1 - 409.93 drams). -0- - See more at:
http://arka.am/en/news/society/eli_lilly_warns_that_armenian_health_ministry_abou t_to_buy_poor_quality_and_expensive_insulin_for_ch/#sthash.y5UTS9LP.dpuf